Literature DB >> 9023651

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.

S L Croft1, D Snowdon, V Yardley.   

Abstract

The in-vitro activities of four anticancer alkyllysophospholipids, ET-18-OCH3 (edelfosine), hexadecylphosphocholine (miltefosine), ilmofosine and SRI 62-834, were determined with ED50 values for Leishmania donovani and Trypanosoma cruzi amastigotes between 0.2 and 5.0 microM and for Trypanosoma brucei trypomastigotes between 7.0 and 50.8 microM. In BALB/c mice miltefosine and ilmofosine were the most active compounds with ED50 values of 2.9 and 14.5 mg/kg x 5 doses against L. donovani and a suppressive effect on T. cruzi infections at 30 mg/kg x 5 doses.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9023651     DOI： 10.1093/jac/38.6.1041

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  41 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 4.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

5.  Synthesis and antileishmanial activities of novel 3-substituted quinolines.

Authors:  André Gustavo Tempone; Ana Cláudia Melo Pompeu da Silva; Carlos Alberto Brandt; Fernanda Scalzaretto Martinez; Samanta Etel Treiger Borborema; Maria Amélia Barata da Silveira; Heitor Franco de Andrade
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.

Authors:  K Seifert; M Duchêne; W H Wernsdorfer; H Kollaritsch; O Scheiner; G Wiedermann; T Hottkowitz; H Eibl
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

8.  Antimicrobial activity of euplotin C, the sesquiterpene taxonomic marker from the marine ciliate Euplotes crassus.

Authors:  Dianella Savoia; Claudio Avanzini; Tiziano Allice; Emanuela Callone; Graziano Guella; Fernando Dini
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Possible mechanism of miltefosine-mediated death of Leishmania donovani.

Authors:  Navin K Verma; Chinmoy S Dey
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Evaluation of the effect of miltefosine on Trichomonas vaginalis.

Authors:  Débora Afonso Silva Rocha; Ivone de Andrade Rosa; Wanderley de Souza; Marlene Benchimol
Journal:  Parasitol Res       Date:  2013-12-22       Impact factor: 2.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.